Single dose ivabradine versus intravenous metoprolol for heart rate reduction before coronary computed tomography angiography (CCTA) in patients receiving long-term calcium channel-blocker therapy

Basit Öğe Kaydı
dc.authorid0000-0002-8118-4547en_US
dc.contributor.authorCelik, O.
dc.contributor.authorAtasoy, M. M.
dc.contributor.authorErturk, M.
dc.contributor.authorYalcin, A. A.
dc.contributor.authorAksu, H. U.
dc.contributor.authorDiker, M.
dc.contributor.authorAkturk, I. F.
dc.contributor.authorAtasoy, I.
dc.date.accessioned2024-07-12T21:44:22Z
dc.date.available2024-07-12T21:44:22Z
dc.date.issued2014en_US
dc.departmentMaltepe Üniversitesien_US
dc.description.abstractBackground: In patients with contraindication for beta-blockers who are also under long-term calcium channel-blocker therapy for any reason, ivabradine may be used as an alternative treatment to achieve the target heart rate. Purpose: To assess whether single dose oral ivabradine in patients referred for coronary computed tomography angiography (CCTA) is safe and can significantly decrease heart rate compared to intravenous (i.v.) metoprolol in patients receiving long-term calcium channel-blocker therapy. Material and Methods: One-hundred and twenty patients who were under calcium channel-blocker therapy referred for CCTA were randomized to premedication with single dose (15 mg) ivabradine (n 63) or i. v. metoprolol (5-10 mg) (n = 62). Hearth rate (HR) was assessed at admission (HR1), prescan (HR2), and during CCTA scan (HR3) for all patients. Blood pressure (BP) was measured before medication (BP1) and immediately before CCTA scan (BP2). Results: Although the HR averages of two groups were not significantly different before medication (HRIv1 = 80 +/- 7 bpm vs. HR beta 1 = 81 +/- 7 bpm; P 0.42), significant HR reduction was observed in the ivabradine group (HRIv3 = 62 +/- 7 bpm) when compared to the metoprolol group (HR beta 3 = 66 +/- 6 bpm; P = 0.001). Decreases in HR forivabradine (18 +/- 6 bpm) was significantly higher than for metoprolol (15 +/- 4 bpm; P = 0.003) without relevant sideeffects. Ivabradine showed no significant effect on either systolic BP or diastolic BP (siBPIv1, 139 +/- 10; siBPIv2, 138 +/- 10; P = 0.260; diBPIv1, 81 +/- 7; diBPIv2, 81 +/- 6; P = 0.59). Nevertheless, metoprolol group demonstrated significant reduction in both SiBP and DiBP (siBP beta 1, 136 +/- 11; siBP beta 2 130 +/- 11; P < 0.001; diBP beta 1, 81 +/- 6; diBP beta 2, 78 +/- 6; P < 0.001). Conclusion: Single dose ivabradine is safe and significantly more effective than i. v. metoprolol in decreasing HR in patients under calcium channel-blocker therapy.en_US
dc.identifier.doi10.1177/0284185113505276
dc.identifier.endpage681en_US
dc.identifier.issn0284-1851
dc.identifier.issn1600-0455
dc.identifier.issue6en_US
dc.identifier.pmid24052362en_US
dc.identifier.scopus2-s2.0-84904008718en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage676en_US
dc.identifier.urihttps://dx.doi.org/10.1177/0284185113505276
dc.identifier.urihttps://hdl.handle.net/20.500.12415/7718
dc.identifier.volume55en_US
dc.identifier.wosWOS:000338447900006en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSAGE PUBLICATIONS LTDen_US
dc.relation.ispartofACTA RADIOLOGICAen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKY00070
dc.subjectIvabradineen_US
dc.subjectheart rateen_US
dc.subjectcoronary CT angiographyen_US
dc.subjectcalcium channelblockeren_US
dc.titleSingle dose ivabradine versus intravenous metoprolol for heart rate reduction before coronary computed tomography angiography (CCTA) in patients receiving long-term calcium channel-blocker therapyen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu